Travere Therapeutics Inc Ordinary Shares TVTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
-
Calliditas Therapeutics stock jumps as kidney treatment gets FDA approval
-
Travere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU Treatments
-
Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial
Trading Information
- Previous Close Price
- $13.65
- Day Range
- $13.82–15.46
- 52-Week Range
- $5.12–15.46
- Bid/Ask
- $15.25 / $17.50
- Market Cap
- $1.16 Bil
- Volume/Avg
- 3.2 Mil / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 380
- Website
- https://www.travere.com
Comparables
Valuation
Metric
|
TVTX
|
AVIR
|
AKBA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 68.90 | 0.59 | — |
Price/Sales | 5.91 | — | 1.50 |
Price/Cash Flow | — | — | 25.58 |
Price/Earnings
TVTX
AVIR
AKBA
Financial Strength
Metric
|
TVTX
|
AVIR
|
AKBA
|
---|---|---|---|
Quick Ratio | 2.89 | 18.87 | 0.65 |
Current Ratio | 3.04 | 19.02 | 1.04 |
Interest Coverage | −35.20 | — | −4.41 |
Quick Ratio
TVTX
AVIR
AKBA
Profitability
Metric
|
TVTX
|
AVIR
|
AKBA
|
---|---|---|---|
Return on Assets (Normalized) | −9.03% | −23.62% | −14.83% |
Return on Equity (Normalized) | −47.00% | −25.11% | — |
Return on Invested Capital (Normalized) | −13.68% | −29.21% | −138.34% |
Return on Assets
TVTX
AVIR
AKBA
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk AS ADR
NVO
| Nckcbvgxg | Qqsf | $516.0 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Nclgjpq | Bhtsz | $117.1 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Fwnzjtrst | Wtgkhv | $111.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Zxyzxpj | Vblpv | $34.6 Bil | |||
argenx SE ADR
ARGX
| Jrjjrxqx | Jfw | $33.0 Bil | |||
BioNTech SE ADR
BNTX
| Scfsvmzvv | Nlht | $28.5 Bil | |||
Moderna Inc
MRNA
| Fslwkrxy | Zzw | $23.5 Bil | |||
United Therapeutics Corp
UTHR
| Nbyfcqxn | Mvzr | $15.6 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Wwjspjbp | Kcshmpl | $13.0 Bil | |||
Incyte Corp
INCY
| Rkqccxp | Mzwrmw | $12.9 Bil |